Syneron Bio Closes Nearly $100M in Series A and A+ Rounds
PR Newswire —
BEIJING, Dec. 18, 2025 /PRNewswire/ -- Syneron Bio, an macrocyclic peptide drug discovery company driven by intelligent high-throughput platform, has successfully completed its Series A and A+ financing rounds, raising close to USD 100 million in total. Top-tier investors participated in...